Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past hour
Any time
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
40m
Intellia Therapeutics: Promising Phase 2 Results and Attractive Valuation Spur Buy Recommendation
JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...
47m
Intellia Therapeutics presents results from Phase 2 study of NTLA-2002
Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Workers reject new contract
Settles civil lawsuit
Suffers 'debilitating' stroke
Joins Republican Party
Accused of plagiarism
'Tarzan' star Ron Ely dies
Courthouse attack charges
Oldest person in US dies
Court orders new sentence
Grizzly bear fatally struck
DOJ warns Musk's PAC?
Kristy now Category 4
Reporter struck by shrapnel
Sued by ‘ring boys’
911 calls from rally released
Pneumococcal vax advice
Carbon removal firms report
Data privacy violations fine
Seeks WI ballot exit
Georgia repels cyberattack
Wins EU antitrust case
New lead dust standards
Unveils new AI rules
Israeli strike on school
To join Harris at rally
US charges media tycoon
Georgia citizenship audit
$135 million in Gaza aid
Hikes annual pass prices
PA provisional ballot ruling
Weekly jobless claims fall
Related topics
CRISPR
Hae
NTLA-2002
Feedback